Experimental GSK drug makes patients smell bad, fails to stop heart attacks

Monday, April 21, 2014 by: Jonathan Benson, staff writer
Tags: failed experimental drug, bad smell, heart attacks

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
Biologist explains how marijuana causes tumor cells to commit suicide
Companies begin planting microchips under employees' skin
NJ cops bust teenagers shoveling snow without a permit
Chemotherapy kills cancer patients faster than no treatment at all
U2's Bono partners with Monsanto to destroy African agriculture with GMOs
FDA targets Dr. Bronner's Magic Soaps for sharing health benefits of coconut oil
Italian court rules mercury and aluminum in vaccines cause autism: US media continues total blackout of medical truth
Orthorexia Nervosa - New mental disorder aimed at people who insist on eating a clean diet
Whooping cough outbreak at Massachusetts high school affected only vaccinated students
Inuit Elders tell NASA Earth Axis Shifted
Vaccine flu shots still contain 25 micrograms mercury - 100 times the concentration of 'mercury-loaded' fish
Measles outbreak likely caused by vaccinated children, science shows
Baby formula is loaded with GMOs - Avoid these brands
Extreme trauma from male circumcision causes damage to areas of brain
Terminal stage IV lung cancer patient miraculously cured by cannabis oil
Costco stops selling antibiotic laden chicken in response to consumer demand
FDA cracks down Walmart, GNC, other companies selling supplements that do not contain the herbs on the label
McDonald's french fries found to contain Silly Putty ingredient and petroleum chemical

(NaturalNews) In a failed attempt to plagiarize what nature already freely provides in the form of anti-inflammatory plants and herbs such as cannabis and turmeric, U.K.-based drug giant GlaxoSmithKline (GSK) is now reaping the bitter harvest of bio-piracy after one of its experimental heart drugs turned out to be both useless and harmful, causing patients to emit a constant vile odor while on the medication.

The results of a Phase III clinical trial recently published in The New England Journal of Medicine revealed darapladib, once believed to be the most promising emerging therapy in GSK's drug pipeline, to be a complete failure therapeutically. Not only does the drug provide no actual benefits for heart patients, but it also puts them at risk of developing foul odors in their urine, feces and skin.

Dubbed by some in the media as GSK's "stinkbomb" drug, darapladib proved to be no better than a placebo at protecting patients with chronic coronary heart disease against cardiac events, despite company claims to the contrary. And worse is the fact that darapladib appears to poison the vital fluids of the body, releasing a dank stench that is sure to deter any rational person from agreeing to continue taking it.

According to the study, 15,828 patients with stable coronary heart disease were assigned to take either a once-daily 160 milligram dose of darapladib or a placebo. The researchers involved hoped to identify a significant reduction in coronary events among those taking the drug as opposed to the placebo, particularly in terms of myocardial infarction, stroke and ultimately cardiovascular death.

But no such benefits were observed, despite rigorous attempts by the GSK-backed team to arrive at such findings. On the contrary, those taking darapladib experienced a negligible overall reduction in cardiac events overall, while also having to deal with the added burden of a persistently foul bodily stench brought about by the drug.

"[I]n patients with stable coronary heart disease... [d]arapladib did not significantly reduce the rate of the primary end point of cardiovascular death, myocardial infarction, or stroke," wrote the authors in their conclusion.

GSK attempts to spin findings, claims darapladib is still effective even though it's not

Following the publishing of these unfavorable results, GSK immediately went into spin mode, claiming that darapladib is still a promising heart drug. GSK's CEO Andrew Witty, in fact, explained to reporters his belief that the findings show "interesting potential signals," a statement of pure derangement considering that no benefits were observed.

"No matter how badly a drug fails in Phase III, investigators and the companies that employ them often bend over backward to highlight any positive sign of efficacy, no matter how weak the signal," wrote John Carroll for FierceBiotech about GSK's position. "And GlaxoSmithKline's team at the American College of Cardiology meeting... was in full spin mode with their heart drug darapladib."

Carroll speaks, of course, of a recent meeting at which GSK tried to exaggerate the findings of the study to make darapladib seem promising, even though the data clearly show it is not. Still, GSK plans to move forward with further trials, obviously aware of the fact that the U.S. Food and Drug Administration (FDA) often approves useless and dangerous drugs when the right wheels are greased.

"It seems the pharmaceutical industry has found that creating a less 'useless' drug has potential to make them more money," wrote one mindful commenter over at FierceBiotech.

Sources for this article include:





Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...


Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.